Full Text View  
  Tabular View  
  Contacts and Locations  
  No Study Results Posted  
  Related Studies  
A New Therapeutic Strategy for Urethral Sphincter Insufficiency
This study is currently recruiting participants.
Verified by Assistance Publique - Hôpitaux de Paris, September 2007
Sponsored by: Assistance Publique - Hôpitaux de Paris
Information provided by: Assistance Publique - Hôpitaux de Paris
ClinicalTrials.gov Identifier: NCT00472069
  Purpose

Stress urinary incontinence is a frequent condition that can be caused by urethral sphincter insufficiency and results in a dramatic deterioration of the quality of life. We developed a new therapeutic strategy for stress urinary incontinence based on the implantation myofibers with their satellite cells in the urethra. The aim of this procedure is to generate functional tissue acting like a new sphincter in the urethra


Condition Intervention Phase
Stress Urinary Incontinence
Striated Urethral Sphincter Insuffisciency
Procedure: transplantation of the squeletic muscular cells
Phase I

MedlinePlus related topics: Pelvic Support Problems Urinary Incontinence
U.S. FDA Resources
Study Type: Interventional
Study Design: Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Efficacy Study
Official Title: EVALUATION Of A NEW THERAPEUTIC STRATEGY FOR URETHRAL SPHINCTER INSUFFICIENCY BASED ON THE INTRA-URETHRAL IMPLANTATION OF AUTOLOGOUS MYOFIBERS WITH THEIR SATELLITE CELLS

Further study details as provided by Assistance Publique - Hôpitaux de Paris:

Primary Outcome Measures:
  • Clinical tolerance and feasibility of a new therapeutic strategy for stress urinary incontinence based on intra urethral myofiber implantation of autologous myofibers with their satellite cells [ Time Frame: 3 months ]

Secondary Outcome Measures:
  • Effects of this treatment on urinary continence in order to consider a phase II later on. [ Time Frame: 3 months ]

Estimated Enrollment: 10
Study Start Date: April 2007
Estimated Study Completion Date: October 2008
Arms Assigned Interventions
A: Experimental Procedure: transplantation of the squeletic muscular cells

Detailed Description:

stress urinary incontinence is a frequent condition that can be caused by urethral sphincter insufficiency and results in a dramatic deterioration of the quality of life. We developed a new therapeutic strategy for stress urinary incontinence based on the implantation myofibers with their satellite cells. The principle of this procedure relies on the activation in vivo of the satellite cells present around each myofibers. Satellite cell activation is concomitant with myofiber death that occurs after their implantation. Activated satellite proliferate and fuse to form myotubes replacing the parental myofibers thus leading to the reconstitution of the muscle mass that was initially implanted. Preliminary studies in the pig showed the regenerated muscle tissue in the urethra was innervated by urethral nerves and developed tonic contractions acting like a new sphincter. This procedure does not include a phase of satellite cell amplification ex vivo, as standard methods of satellite cell transfer, and rather relies on the natural myogenic capacities of these cells. Thus, the procedure of cell transfer into the urethra is considerably simplified and can be performed in one step in the operating room.This therapeutic strategy could represent an alternative to the artificial urinary sphincter.

  Eligibility

Ages Eligible for Study:   40 Years to 75 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Men or women from 40 to 75 years old, suffering from urinary incontinence since at least 6 months and candidate for a surgical treatment (artificial urinary sphincter, synthetic compressive tapes or adjustable balloons).

The myofiber implantation procedure will be proposed after failure of pelvic floor exercises.

  • The observation of urine leakage during cough in consultation or during urodynamic (with absence of abnormal vesical contraction) and a score MHU > 2 (domain of stress urinary incontinence) will be considered as the main diagnostic criteria.
  • An urethral closure pressure lower than 40 cm H20 will be the main urodynamic diagnostic criterion
  • For women: a negative BONNEY test, and Qtip test<40° (c.f. annex) demonstrating the absence of vesica-urethral hypermobility.

    24 hours Pad test > 20g.

Exclusion Criteria:

  • Incapacity to answer the questionnaires of evaluation.
  • History of pelvic radiotherapy.
  • Disorder of hemostasis.
  • Untreated urinary infection.
  • Genetically determined or acquired muscular disease.
  • Neurological disorder (Parkinson's disease, multiple sclerosis, spina bifida, medullary traumatism).
  • The patients suffering from stress urinary incontinence due to vesica-urethral hypermobility (positive BONNEY test and Qtip test >40°) will not be included in the study because the referenced treatment is the implantation of a vaginal tape supporting the urethra.
  • Incomplete vesical emptying. Residual volume > 20% of the urinated volume with a micturition >150cc.
  • Dysuria: maximum urinary flow < 12 ml/sec, IPSS score>7 or score (men) or MHU dysuria domain none equal to 0 at woman.
  • Vesical instability (bladder contraction > 10 cm H20 during the vesical filling of the cysto-manometry). bladder capacity (B3) < 300 DC.
  • Urethral Stenosis (ureterocystoscopy).
  • Previous surgeries for urinary incontinence do not constitute a criterion of exclusion.
  • Pregnancy or intention of pregnancy throughout study. A test of pregnancy will be carried out with the visit of inclusion.
  • Urethral diverticulum.
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00472069

Contacts
Contact: René YIOU, MD,PhD +33(0)1 49 81 25 53 rene.yiou@hmn.aphp.fr

Locations
France
Hopital Henri Mondor service Urologie Recruiting
CRETEIL, France, 94010
Contact: René YIOU, MD,PhD     +33(0) 1 49 81 25 53     rene.yiou@hmn.aphp.fr    
Sponsors and Collaborators
Assistance Publique - Hôpitaux de Paris
Investigators
Principal Investigator: René YIOU, MD,PhD Assistance Publique - Hôpitaux de Paris
  More Information

Study ID Numbers: P060505
Study First Received: May 10, 2007
Last Updated: September 18, 2007
ClinicalTrials.gov Identifier: NCT00472069  
Health Authority: France: Ministry of Health

Keywords provided by Assistance Publique - Hôpitaux de Paris:
Stress Urinary Incontinence
striated urethral sphincter insufficiency
myofibers
satellite cells
myotubes
urethral
Muscle fibres

Study placed in the following topic categories:
Signs and Symptoms
Urinary Incontinence, Stress
Urologic Diseases
Urination Disorders
Stress
Urinary Incontinence

Additional relevant MeSH terms:
Urological Manifestations

ClinicalTrials.gov processed this record on January 14, 2009